Total neoadjuvant therapy is associated with improved overall survival and pathologic response in pancreatic adenocarcinoma.
cancer
neoadjuvant
outcomes
pancreas
survival
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
revised:
10
04
2022
received:
15
12
2021
accepted:
18
04
2022
pubmed:
28
4
2022
medline:
2
8
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Few studies have evaluated outcomes of total neoadjuvant therapy (TNT) compared with single modality neoadjuvant therapy (SMNT) or surgery first (SF) for pancreatic ductal adenocarcinoma (PDAC). A single-institution retrospective review of PDAC patients who underwent pancreatectomy was conducted (1993-2019). Overall survival (OS) estimates from diagnosis and from surgery were determined using Kaplan-Meier methods; Cox proportional hazards models adjusted for covariates. Surgery was performed upfront (SF) in 168 (46.9%), while 111 (31.0%) had chemotherapy or chemoradiation before resection (SMNT), and 79 (22.1%) underwent TNT (chemotherapy and chemoradiation). Resection margins were more frequently R0 in the TNT group (86.1%) compared with SMNT (64.0%) and SF (72%) (p < 0.001). Complete pathologic response was more common in the TNT group (10.1%) compared with SMNT (3.6%) or SF (0.6%) (p = 0.001), resulting in prolonged survival (median OS = 100.2 months). TNT patients demonstrated longer median OS from surgery (33.6 months) compared with SF (19.1 months) and SMNT (17.4 months) (p = 0.010), which persisted after controlling for covariates. TNT is associated with more frequent complete pathologic response, a higher rate of margin negative resection, and prolonged OS as compared with SF or SMNT. Additional studies to identify subgroups that derive the greatest benefit are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Few studies have evaluated outcomes of total neoadjuvant therapy (TNT) compared with single modality neoadjuvant therapy (SMNT) or surgery first (SF) for pancreatic ductal adenocarcinoma (PDAC).
METHODS
METHODS
A single-institution retrospective review of PDAC patients who underwent pancreatectomy was conducted (1993-2019). Overall survival (OS) estimates from diagnosis and from surgery were determined using Kaplan-Meier methods; Cox proportional hazards models adjusted for covariates.
RESULTS
RESULTS
Surgery was performed upfront (SF) in 168 (46.9%), while 111 (31.0%) had chemotherapy or chemoradiation before resection (SMNT), and 79 (22.1%) underwent TNT (chemotherapy and chemoradiation). Resection margins were more frequently R0 in the TNT group (86.1%) compared with SMNT (64.0%) and SF (72%) (p < 0.001). Complete pathologic response was more common in the TNT group (10.1%) compared with SMNT (3.6%) or SF (0.6%) (p = 0.001), resulting in prolonged survival (median OS = 100.2 months). TNT patients demonstrated longer median OS from surgery (33.6 months) compared with SF (19.1 months) and SMNT (17.4 months) (p = 0.010), which persisted after controlling for covariates.
CONCLUSIONS
CONCLUSIONS
TNT is associated with more frequent complete pathologic response, a higher rate of margin negative resection, and prolonged OS as compared with SF or SMNT. Additional studies to identify subgroups that derive the greatest benefit are warranted.
Identifiants
pubmed: 35476892
doi: 10.1002/jso.26906
pmc: PMC9340441
mid: NIHMS1800367
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-512Subventions
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA006927
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA006927
Pays : United States
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
JAMA Oncol. 2021 Mar 1;7(3):421-427
pubmed: 33475684
HPB (Oxford). 2020 Nov;22(11):1569-1576
pubmed: 32063480
J Clin Oncol. 2020 Jun 1;38(16):1763-1773
pubmed: 32105518
Ann Surg. 2018 Jul;268(1):1-8
pubmed: 29334562
JAMA Oncol. 2018 Jul 1;4(7):963-969
pubmed: 29800971
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Ann Surg Oncol. 2021 Apr;28(4):2246-2256
pubmed: 33000372
Pancreas. 2020 Aug;49(7):897-903
pubmed: 32658070
J Gastrointest Surg. 2008 Apr;12(4):701-6
pubmed: 18027062
Surgery. 2012 Sep;152(3 Suppl 1):S43-9
pubmed: 22763261
Cancer Med. 2016 Oct;5(10):2825-2831
pubmed: 27671746
JAMA Surg. 2016 Aug 17;151(8):e161137
pubmed: 27275632
Ann Surg Oncol. 2009 Jul;16(7):1751-6
pubmed: 19390900
Ann Surg. 2021 Feb 1;273(2):341-349
pubmed: 30946090
Ann Surg Oncol. 2013 Aug;20(8):2787-95
pubmed: 23435609
Ann Surg. 2019 Sep;270(3):400-413
pubmed: 31283563
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490